Calidi Biotherapeutics, Inc. (CLDI) Key Metrics
CLDI valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $3.1M
- Enterprise value
- $687,760
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 50.8
- Price / book
- 0.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.33
CLDI key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCLDI returns How much profit the business earns on the capital it uses.
CLDI financial health Debt, liquidity and how easily interest is covered.
CLDI efficiency & capital use Working capital cycle and where the cash goes.
CLDI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CLDI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CLDI cash returned to shareholders
CLDI key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Share price at fiscal year-end | $18.72 | $220.80 | $2,899.20 | $19,526.40 | $18,835.20 | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −752.2% | — | — | — | — | — |
| Return on assets (ROA) | −172.8% | −183.0% | −463.2% | −849.3% | −417.1% | −428.6% |
| Return on tangible assets | −224.7% | −156.1% | −291.6% | −979.1% | −322.4% | −428.6% |
| Financial health | ||||||
| Total debt | $2.6M | $7.0M | $7.2M | $6.0M | $5.2M | $11.7M |
| Cash & short-term investments | $5.6M | $9.6M | $2.0M | $372,000 | $2.1M | $420,000 |
| Net debt | −$3.0M | −$2.6M | $5.2M | $5.6M | $3.0M | $11.3M |
| Debt / equity | 0.68 | 4.59 | — | — | — | — |
| Debt / assets | 0.29 | 0.50 | 0.72 | 2.31 | 1.53 | 6.33 |
| Current ratio | 1.59 | 1.08 | 0.42 | 0.02 | 0.11 | 0.06 |
| Quick ratio | 1.59 | 1.08 | 0.42 | 0.02 | 0.11 | 0.06 |
| Interest coverage | -97.8 | -23.3 | -7.7 | -146.4 | -17.1 | -41.6 |
| Working capital | $2.3M | $731,000 | −$5.9M | −$42.2M | −$23.2M | −$8.4M |
| Invested capital | $723,000 | −$1.0M | −$3.0M | −$44.8M | −$19.6M | −$11.2M |
| Tangible asset value | $3.8M | $2.0M | −$8.2M | −$50.4M | −$22.6M | −$22.5M |
| Net current asset value | $1.2M | −$2.0M | −$14.0M | −$52.3M | −$23.3M | −$23.8M |
| Capital allocation | ||||||
| Dividends paid | $5.7M | $1.7M | — | — | — | — |
| Share buybacks (net) | — | — | — | — | $0 | $175,000 |
| Capex / revenue | — | — | — | 951.1% | 45.9% | — |
| Capex / depreciation | 0.07 | 0.01 | 0.47 | 1.69 | 1.35 | 1.91 |
| Stock-based compensation / revenue | — | — | — | 13,651.1% | 295.5% | — |
| R&D / revenue | — | — | — | 16,126.7% | 1,041.0% | — |
| SG&A / revenue | — | — | — | 35,337.8% | 1,372.6% | — |
| Efficiency | ||||||
| Days sales outstanding | — | — | — | 7.1 | — | — |
| Days payables outstanding | 294.8 | 588.4 | 726.7 | 1,830.3 | 2,807.4 | — |
| Cash conversion cycle (days) | — | — | — | -1,823.3 | — | — |
| Receivables turnover | — | — | 0.00 | 51.72 | — | — |
| Payables turnover | 1.24 | 0.62 | 0.50 | 0.20 | 0.13 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.17 | 0.00 |
| Average receivables | — | — | $680,435 | $870 | — | — |
| Average payables | $1.3M | $2.5M | $2.5M | $1.4M | $723,000 | $822,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CLDI's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CLDI valuation and financial ratios
Calidi Biotherapeutics earned a return on equity of −752.2% in fiscal 2025. It ended the year with $2.6 million of debt and $5.6 million in cash and short-term investments, a net cash position of $3.0 million. It returned $5.7 million to shareholders: $5.7 million in dividends and $0 in share buybacks.
See the CLDI income statement, the CLDI chart for price history, or the CLDI stock overview for the latest quote and news.
CLDI key metrics FAQ
What is Calidi Biotherapeutics's return on equity?
Calidi Biotherapeutics's return on equity (ROE) was −752.2% in fiscal 2025: net income of -$19.9 million on average shareholders' equity of $2.6 million.
How much debt does Calidi Biotherapeutics have?
Calidi Biotherapeutics had total debt of $2.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.68 and more cash than debt.
What is Calidi Biotherapeutics's current ratio?
Calidi Biotherapeutics's current ratio was 1.59 at the end of fiscal 2025: current assets were 1.59 times current liabilities.